Compare STRIDES PHARMA SCIENCE with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs FDC LTD. - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE FDC LTD. STRIDES PHARMA SCIENCE/
FDC LTD.
 
P/E (TTM) x 14.4 16.2 89.0% View Chart
P/BV x 0.9 2.2 38.8% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   FDC LTD.
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
FDC LTD.
Mar-18
STRIDES PHARMA SCIENCE/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,147319 359.6%   
Low Rs642164 391.5%   
Sales per share (Unadj.) Rs317.261.6 514.6%  
Earnings per share (Unadj.) Rs7.89.9 78.8%  
Cash flow per share (Unadj.) Rs25.112.0 209.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.373.2 374.8%  
Shares outstanding (eoy) m89.50174.40 51.3%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.83.9 72.0%   
Avg P/E ratio x114.024.3 469.7%  
P/CF ratio (eoy) x35.720.2 176.9%  
Price / Book Value ratio x3.33.3 98.8%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,05842,118 190.1%   
No. of employees `0002.55.5 45.3%   
Total wages/salary Rs m4,3412,167 200.3%   
Avg. sales/employee Rs Th11,325.81,943.7 582.7%   
Avg. wages/employee Rs Th1,731.4391.7 442.0%   
Avg. net profit/employee Rs Th280.1313.7 89.3%   
INCOME DATA
Net Sales Rs m28,39410,751 264.1%  
Other income Rs m941510 184.6%   
Total revenues Rs m29,33411,260 260.5%   
Gross profit Rs m3,9652,267 174.9%  
Depreciation Rs m1,540351 438.4%   
Interest Rs m1,96214 14,017.1%   
Profit before tax Rs m1,4032,411 58.2%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97671 14.5%   
Profit after tax Rs m7021,735 40.5%  
Gross profit margin %14.021.1 66.2%  
Effective tax rate %6.927.8 24.9%   
Net profit margin %2.516.1 15.3%  
BALANCE SHEET DATA
Current assets Rs m24,8367,213 344.3%   
Current liabilities Rs m18,9932,104 902.8%   
Net working cap to sales %20.647.5 43.3%  
Current ratio x1.33.4 38.1%  
Inventory Days Days7154 130.2%  
Debtors Days Days11328 409.0%  
Net fixed assets Rs m34,2896,865 499.5%   
Share capital Rs m895175 510.8%   
"Free" reserves Rs m23,65112,586 187.9%   
Net worth Rs m24,54612,761 192.3%   
Long term debt Rs m15,5136 258,553.3%   
Total assets Rs m65,43715,041 435.1%  
Interest coverage x1.7173.2 1.0%   
Debt to equity ratio x0.60 134,420.2%  
Sales to assets ratio x0.40.7 60.7%   
Return on assets %4.111.6 35.0%  
Return on equity %2.913.6 21.0%  
Return on capital %6.919.0 36.4%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6971,889 831.0%   
Fx outflow Rs m7350-   
Net fx Rs m14,9621,889 792.1%   
CASH FLOW
From Operations Rs m1,8711,498 124.8%  
From Investments Rs m5,826201 2,897.0%  
From Financial Activity Rs m-10,157-1,694 599.5%  
Net Cashflow Rs m-2,61510 -25,387.3%  

Share Holding

Indian Promoters % 27.7 68.9 40.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.7 804.3%  
FIIs % 8.6 7.5 114.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 19.0 136.3%  
Shareholders   56,241 23,730 237.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 22, 2019 03:37 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS